Current Clinical Trials
Impact of a ketogenic diet on metabolic and psychiatric health in patients with schizophrenia or bipolar illness*
To initiate a low-carbohydrate, high-fat ketogenic dietary intervention among a small cohort of outpatients with either schizophrenia or bipolar illness and comorbid overweight/obesity currently taking psychotropic medications.
Stanford-affiliated
FDA Approved Medication to Reduce Binge Eating and/or Purging*
This study will demonstrate the efficacy of Qsymia versus placebo in treating bulimia nervosa and binge eating disorder.
Stanford-affiliated
Ketogenic diet for psychotic disorders
This randomised, controlled pilot study aims to investigate the feasibility of a Modified Ketogenic Diet intervention protocol in psychotic inpatients, and the potential impact of this intervention on psychotic symptoms, depressive and anxiety symptoms, and functioning in patients with psychotic symptoms / psychotic disorder.
Externally-conducted